1 Singapore Health Services, Singapore.
2 National Cencer Centre Singapore, Singapore.
Otolaryngol Head Neck Surg. 2019 Apr;160(4):642-650. doi: 10.1177/0194599818815065. Epub 2018 Dec 18.
There are no well-defined treatment recommendations for elderly patients with advanced head and neck squamous cell carcinoma. This study aimed to investigate whether aggressive treatment among the elderly translated into better survival outcomes.
Retrospective cohort study.
Single tertiary institution.
Elderly patients (≥60 years) with advanced-stage head and neck squamous cell carcinoma (stage III and IV) treated between January 1991 and May 2014 were reviewed. According to current National Comprehensive Cancer Network guidelines, they were classified to have received standard or substandard treatment. Overall survival (OS), locoregional recurrence-free survival, and distant recurrence-free survival were evaluated.
A total of 355 patients were treated curatively: 194 with up-front surgery and 161 with radiotherapy or concurrent chemotherapy and radiotherapy. Median OS was higher among patients who received standard treatment (42.0 vs 16.0 months, P < .001). On multivariate analysis, standard treatment showed superior OS ( P < .001). Use of substandard treatment showed a hazard ratio of 2.09 (95% CI, 1.59-2.74) for poorer OS.
Aggressive standard treatment protocols should be advocated for elderly patients, where comorbidities permit, as they confer better outcomes.
对于晚期头颈部鳞状细胞癌的老年患者,目前尚无明确的治疗建议。本研究旨在探讨老年患者的积极治疗是否能转化为更好的生存结果。
回顾性队列研究。
单一的三级机构。
回顾性分析了 1991 年 1 月至 2014 年 5 月期间治疗的晚期头颈部鳞状细胞癌(III 期和 IV 期)的老年患者(≥60 岁)。根据现行国家综合癌症网络指南,他们被分为接受标准或不标准治疗。评估总生存(OS)、局部区域无复发生存和远处无复发生存。
共有 355 例患者接受了根治性治疗:194 例接受了术前手术,161 例接受了放疗或同期放化疗。接受标准治疗的患者中位 OS 更高(42.0 与 16.0 个月,P<0.001)。多因素分析显示,标准治疗具有更好的 OS(P<0.001)。使用不标准治疗的 OS 较差的风险比为 2.09(95%CI,1.59-2.74)。
在合并症允许的情况下,应提倡为老年患者提供积极的标准治疗方案,因为这能带来更好的结果。